Study: Fish oil supplements reduce cognitive decline, brain atrophy in older people -
Alzheimer's disease affects more than 5 million every year US
Rhode Island the hospital researchers completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older people. The study examined the relationship between the FOS used in the Alzheimer Neuroimaging Initiative diseases (ADNI) and indicators of cognitive decline. The results are published online ahead of print in the journal Alzheimer's and dementia .
"At least one person is diagnosed every minute with the disease (AD) Alzheimer's and despite all efforts, we have not yet found a cure for this widespread and debilitating disease," said lead researcher Lori Daiello, PharmD, of Alzheimer's disease and memory disorders Center at Rhode Island hospital. "the field is currently engaged in numerous studies to find better treatments for people with AD ;. However, looking for ways to prevent AD or slow cognitive decline in normal aging is of utmost importance "
In this retrospective study, older people involved in the ADNI study was assessed with . neuropsychological tests and brain magnetic resonance imaging (MRI) every six months the group included 229 elderly who were cognitively normal, 397 who were diagnosed with mild cognitive impairment, and 193 with AD
the study found that fish oil supplements use of during the study was associated with significantly lower rates of cognitive decline as measured by disease Alzheimer's disease assessment Scale ( ADAS-cog) and the Mini Mental State Exam (MMSE), but this benefit was observed for the group of participants without dementia at the time of registration.
"Furthermore, the imagery cerebral series conducted during this study showed that participants with normal cognition who reported taking fish oil supplements showed less brain shrinkage in key neurological areas, compared to those who do not use supplements, "said Daiello. "In addition, the positive results on cognitive tests and brain MRI were observed in people who do not carry the genetic risk factor best studied for AD, APOE-4. More research is needed, but these results are promising and underscore the need for future studies to expand the current knowledge of the effects of FOS use on cognitive aging and AD. "
It is estimated that over 5 million people in the United States have Alzheimer's disease. It is the most common form of dementia and is the sixth leading cause of death in the United States
EmoticonEmoticon